Trial Profile
A Phase 1, Open-label, Two-part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2018
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 09 Oct 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2015 New trial record